Abstract library

216 results for "Cell lines".
#933 The Cytotoxic Effect of Sunitinib on Human Bronchial Carcinoid Cell Lines and Primary Cultures is Counteracted by EGF and IGF-1, but not by VEGF
Introduction: Bronchial carcinoids (BC) are rare tumors originating from endocrine cells dispersed in the respiratory epithelium. The main BC treatment is surgery, but which is not feasible for large, infiltrating and metastatic disease. In these settings, medical therapy is often tried. Therefore it is important to identify new therapeutic targets and new molecules capable of providing adequate medical treatment for patients with BC. Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase inhibitor.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Teresa Gagliano
Keywords: BC, RTK, Sunitinib
#141 Incidence of second primary tumors in patients with neuroendocrine tumors
Introduction: Based on epidemiological data from SEER 1950-1999, 22.4% cases of non-carcinoid second primary tumors have been described in patients diagnosed with neuroendocrine tumors. The incidence of this type of tumors varies, depending on the series assessed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Juan Manuel OConnor
Authors: Pesce V, OConnor J, Mendez G, Bestani C, ...
#945 Interference of Nutrient/Oxygen Availability with mTOR Activation and Inhibition in Lung Carcinoids: A Tissue and Cellular Study
Introduction: MTOR is capable of coupling cellular nutrient sensing to metabolic homeostasis. However, little is known of the interactions between cancer‐specific metabolic pathways and profiles of responsiveness to mTOR inhibition in neuroendocrine tumors.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Prof Marco Volante
Authors: Rapa I, Giorcelli J, Votta A, Marino G, ...
#1423 Multidisciplinary Management and Patient Flow in Neuroendocrine Tumors (NET): Consensus of a Tertiary Hospital
Introduction: Currently, there has been an improvement in diagnostic procedures and treatments of NET. Therefore, an effective teamwork is needed to choose the best approach for patients.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PhD Paula Jimenez-Fonseca
#387 Combined Blockade of Several Signalling Pathways Shows Marked Anti-Tumor Potential in Two Novel Mouse Phaeochromocytoma Cell Lines
Introduction: The current study explores novel targeted therapies for malignant pheochromocytomas (PCCs) and paragangliomas, utilizing a more benign (MPC) and a more malignant (MTT) PCC cell line. We have previously shown that the dual PI3K/mTORC1 inhibitor NVP-BEZ235 significantly reduced MPC and MTT cell viability, but increased ERK signalling.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Svenja Noelting
#542 Establishment of a Multidisciplinary Tumor Board for Patients with Neuroendocrine Neoplasms
Introduction: Neuroendocrine neoplasms are rare and multiform, requiring a multidisciplinary approach. We report the experience of a neuroendocrine tumor board (TB) established at our University Hospital.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#1528 Medullary Thyroid Carcinoma Cell Lines – An Update
Introduction: Medullary Thyroid Carcinoma (MTC) originates from calcitonin-producing neuroendocrine C-cells of the thyroid gland. Mutations in the RET-proto-oncogene are associated with both sporadic and familial MTC. As MTC are poorly responsive to chemo- and radiation- therapy, surgery is the only curative treatment at the moment. The cytogenetics of MTC have been sparsely investigated because the cells are very difficult to cultivate. In the last three decades our research group has established 10 continues cell lines derived from primary tumor and lymph node metastasis of patients with either sporadic or hereditary MTC.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD Gert Schwach
#1542 Selective Inhibition of PI3Kalpha (BYL719) - Promising Therapeutic Option for Neuroendocrine Tumors?
Introduction: Neuroendocrine tumors are heterogeneous, often functional malignancies and their therapeutic options are limited. As the PI3 kinase signaling is ­in GEP-NENs, selective PI3Kalpha inhibitors may be more potent than panPI3K inhibitors.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PD Dr. Patricia Grabowski
#2101 The Effect of Temozolomide on Pancreatic Neuroendocrine Tumors in Vitro and Role of MGMT and MMR System in Temozolomide Resistance
Introduction: Temozolomide (TMZ) has been suggested as a treatment option for patients with pancreatic neuroendocrine tumours (PNETs). The tumour response to TMZ has been linked to expression levels of O6-methylguanine-DNA methyltransferase (MGMT) and components of the mismatch repair (MMR) system.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Drs. Anela Blazevic
#2196 The Neuroendocrine Phenotype, Genomic Profile, and Therapeutic Sensitivity of GEPNET Cell Lines
Introduction: Patient tumour-derived cell lines have been widely used for studying the molecular mechanisms of tumours and their response to therapy. The establishment of cell lines from gastro-entero-pancreatic neuroendocrine tumours (GEPNETs) has proved difficult, but despite the challenges a limited amount of cell lines now exists.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Tobias Hofving
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.